Figure 1

CD38 inhibition results in high anti-leukemic efficacy in vitro independent of CD38 expression level. (A) Human AML cell lines were either mono- or co-cultured with MS-5 stroma cells or HUVEC cells and treated with 0.1 µg/ml daratumumab or vehicle for 4 days. Absolute numbers of CD45⁺ cells were normalized to mono-cultured control, for each pair the mean change in cell count is given in percentage (n = 3). (B) Primary AML cells (n = 10) or (C) healthy peripheral blood mononuclear cells (n = 6) were mono-, co- or triple-cultured with HUVEC and/or mesenspheres and treated with 0.1 µg/ml daratumumab or vehicle for 3 days. Absolute numbers of CD45⁺ cells were normalized to mono-cultured control. Each dot represents the mean of triplicates, for each pair the mean change in cell count is given in percentage. Data are shown as mean ± SEM. n.s., not significant, *p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001 as determined by unpaired student´s t-test (A) and Wilcoxon signed-rank test (B,C). See also Supplementary Fig. S1.